|
English
|
正體中文
|
简体中文
|
總筆數 :0
|
|
造訪人次 :
52737212
線上人數 :
689
教育部委託研究計畫 計畫執行:國立臺灣大學圖書館
|
|
|
"yen y h"的相關文件
顯示項目 6-15 / 64 (共7頁)
1 2 3 4 5 6 7 > >>
每頁顯示[10|25|50]項目
| 臺大學術典藏 |
2022-03-15T05:39:21Z |
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
|
Lee J.-H.; WEI-WU CHEN; Hsu C.-H.; Yen Y.-H.; Yang J.C.-H.; Cheng A.-L.; Sasaki S.-I.; Chiu L.Y.; Sugihara M.; Ishizuka T.; Oguma T.; Tajima N.; Lin C.-C. |
| 臺大學術典藏 |
2022-03-09T03:12:42Z |
Serum and endometrial markers
|
Yang W.-C.V.; HUEI-WEN CHEN; Au H.-K.; Chang C.-W.; Huang C.-T.; Yen Y.-H.; Tzeng C.-R. |
| 臺大學術典藏 |
2022-02-23T02:12:21Z |
Chronic hepatitis B exhibited higher rate of hepatocellular carcinoma occurrence than hepatitis C in cirrhotic patients after effective antiviral treatment
|
Lin M.-T.; Chang K.-C.; Yen Y.-H.; Tsai M.-C.; CHIEN-HUNG CHEN; Wang J.-H.; Hsiao C.-C.; Chiu Y.-H.; Hu T.-H. |
| 臺大學術典藏 |
2022-02-23T02:12:18Z |
Corrigendum: Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis (Front. Oncol., (2021), 11, (737767), 10.3389/fonc.2021.737767)
|
Kuo Y.-H.; Lu S.-N.; Chen Y.-Y.; Kee K.-M.; Yen Y.-H.; Hung C.-H.; Hu T.-H.; CHIEN-HUNG CHEN; Wang J.-H. |
| 臺大學術典藏 |
2022-02-23T02:12:18Z |
Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
|
Kuo Y.-H.; Lu S.-N.; Chen Y.-Y.; Kee K.-M.; Yen Y.-H.; Hung C.-H.; Hu T.-H.; CHIEN-HUNG CHEN; Wang J.-H. |
| 臺大學術典藏 |
2022-02-22T05:34:11Z |
Chronic hepatitis B exhibited higher rate of hepatocellular carcinoma occurrence than hepatitis C in cirrhotic patients after effective antiviral treatment
|
Lin M.-T.; Chang K.-C.; Yen Y.-H.; Tsai M.-C.; CHIEN-HUNG CHEN; Wang J.-H.; Hsiao C.-C.; Chiu Y.-H.; Hu T.-H. |
| 臺大學術典藏 |
2022-02-22T05:34:08Z |
Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
|
Kuo Y.-H.; Lu S.-N.; Chen Y.-Y.; Kee K.-M.; Yen Y.-H.; Hung C.-H.; Hu T.-H.; CHIEN-HUNG CHEN; Wang J.-H. |
| 臺大學術典藏 |
2022-02-22T05:34:07Z |
Corrigendum: Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis (Front. Oncol., (2021), 11, (737767), 10.3389/fonc.2021.737767)
|
Kuo Y.-H.; Lu S.-N.; Chen Y.-Y.; Kee K.-M.; Yen Y.-H.; Hung C.-H.; Hu T.-H.; CHIEN-HUNG CHEN; Wang J.-H. |
| 臺大學術典藏 |
2022-02-21T03:52:32Z |
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
|
JIH-HSIANG LEE; Chen T.W.-W.; Hsu C.-H.; Yen Y.-H.; Yang J.C.-H.; Cheng A.-L.; Sasaki S.-I.; Chiu L.Y.; Sugihara M.; Ishizuka T.; Oguma T.; Tajima N.; Lin C.-C. |
| 臺大學術典藏 |
2021-08-31T06:29:19Z |
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
|
Lee J.-H.; Chen T.W.-W.; Hsu C.-H.; Yen Y.-H.; Yang J.C.-H.; ANN-LII CHENG; Sasaki S.-I.; Chiu L.Y.; Sugihara M.; Ishizuka T.; Oguma T.; Tajima N.; Lin C.-C. |
顯示項目 6-15 / 64 (共7頁)
1 2 3 4 5 6 7 > >>
每頁顯示[10|25|50]項目
|
